J&J collaborates with Aldeyra on new drugs for systemic inflammatory diseases
A few months after posting mid-stage data suggesting that its lead drug could be on a path to proving its worth in treating various conditions arising from ocular inflammation, Aldeyra Therapeutics $ALDX has scored a collaboration pact with the research arm at J&J.
The proof-of-concept work in dry eye disease and anterior uveitis evidently attracted the pharma to reproxalap. Their drug is an aldehyde sequestering agent, and J&J will now set up a joint steering committee to work on more of this category of agents.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.